BiotechTubeBiotechTube
Home/Pipeline/Inflammation & Immunology Programs

Inflammation & Immunology Programs

Autoimmune Diseases

Phase 2/3Active

Key Facts

Indication
Autoimmune Diseases
Phase
Phase 2/3
Status
Active
Company
Pfizer

About Pfizer

Founded in 1849, Pfizer has evolved into a global biopharmaceutical leader with a comprehensive portfolio spanning vaccines, oncology treatments, and medicines for chronic diseases. The company operates extensive R&D programs across four key therapeutic areas and maintains a robust clinical pipeline with programs in all phases of development. Led by CEO Albert Bourla, Pfizer continues to drive innovation through strategic partnerships and significant investments in breakthrough science.

View full company profile

Therapeutic Areas

OncologyInternal MedicineInflammation & ImmunologyVaccinesCardiovascularDiabetesObesity

Other Autoimmune Diseases Drugs

DrugCompanyPhase
ARGX-118ArgenxPhase 1
Adalimumab biosimilar (IBI303)Innovent BiologicsApproved
Hulio (Adalimumab)BioconApproved
Undisclosed ImmTAAI candidatesImmunocorePreclinical
BHV-1100 (IgG degrader)BiohavenPreclinical
BispecificsShattuck LabsIND-Enabling
Preclinical PipelineAutolus TherapeuticsPre-clinical
FT839Fate TherapeuticsPhase 1
IMP761ImmutepPhase 1 (planned)